Project Grant K08CA301027
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a Project Grant of $133,598.00 under the Cancer Research Manpower program (CFDA 93.398) on June 23, 2025, with completion anticipated by May 31, 2027. This award supports research aimed at developing improved chemoprevention strategies for Familial Adenomatous Polyposis (FAP), a hereditary condition characterized by polyp formation and elevated cancer risk. The principal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a Project Grant of $119,172.00 under the Cancer Research Manpower program (CFDA 93.398) to support research addressing therapeutic response in non-small cell lung cancer (NSCLC). The project, initiated August 1, 2025, and completing July 31, 2027, focuses on developing computational approaches to integrate multi-modal and multi-omics biomedical datasets for improved...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $113,147 to The Leland Stanford Junior University on July 3, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support a five-year career development program for Dr. Chris McGinnis, Ph.D. This Project Grant funds a mentored postdoctoral research training and career development initiative designed to prepare Dr. McGinnis for an independent research career in cancer immunology. The award supports Dr. McGinnis's...
- Federal Project Grant Award Summary The Leland Stanford Junior University received a $135,774 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on July 10, 2025, with a completion date of June 30, 2027. This award supports research training and investigation into tumor suppressor genes (TSGs) and the overdominant model of tumor suppression in oncogenic KRAS-driven lung adenocarcinoma. The research employs advanced molecular and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded a $131,099 Project Grant to The Leland Stanford Junior University, effective July 1, 2025 through June 30, 2027. This award supports a comprehensive investigation of the obesity paradox phenomenon in renal cell cancer (RCC), examining how adiposity-related factors at molecular, individual, and neighborhood levels influence RCC incidence, tumor aggressiveness,...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $584,521 Project Grant on August 8, 2025, under the Cancer Treatment Research program (CFDA 93.395) to investigate subclonal determinants of radiation response in soft tissue sarcomas. The research will deliver three primary products: (1) identification and validation of epigenetic changes, including DNA methylation and chromatin accessibility alterations, that confer radioresistance to...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a Project Grant of $642,732 under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning August 1, 2025, with a completion date of July 31, 2030. The award supports research to unravel heterogeneity in endometrial cancer through integrated single-cell genotype-phenotype mapping. The project addresses the critical need to refine molecular classification, improve...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a Project Grant of $593,557 on March 18, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop magnetic resonance (MR) imaging methods for real-time measurement and control of BPM31510, an emerging lipophilic cancer therapy. The research addresses a critical clinical translation challenge by creating tools to monitor tumor response in real time,...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $368,294 Project Grant effective September 1, 2025, through August 31, 2028, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). The research focuses on developing next-generation platforms for interrogating T-cell receptor (TCR) specificity to identify and detect peptide-MHC tumor antigens. Stanford will optimize two complementary technological approaches: (1)...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Washington $278,494 on August 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support a K08 Mentored Research Scientist Development Award. This five-year project, concluding July 31, 2030, funds the career development and research training of an Assistant Professor of Medicine and primary care physician to become an independent clinician investigator specializing in cancer screening...
Federal Grant Award Summary The National Cancer Institute awarded a $212,332 Project Grant to The Leland Stanford Junior University under the Cancer Research Manpower program (CFDA 93.398) effective May 1, 2026, through April 30, 2031. This award supports a K08 mentored research career development grant designed to develop Dr. Aaron Dawes as an independent investigator focused on access and quality of specialty cancer care. The grant provides mentorship, training, and applied research opportunities to advance Dr. Dawes' research career in examining how Medicaid managed care affects treatment and clinical outcomes for patients with gastrointestinal cancers. The research leverages a natural experiment in California where counties transitioned from fee-for-service to managed care at different times, utilizing linked data from the California Cancer Registry, Medicaid claims, and county-level enrollment data. The project encompasses three primary aims: quantifying the causal effects of Medicaid managed care transition on access, quality, and clinical outcomes using difference-in-differences analysis; exploring differential impacts by cancer type, sex, and area-level social disadvantage; and evaluating policy and implementation factors that may mitigate negative outcomes. This research addresses a critical gap in understanding how comprehensive managed care—which now covers over 85% of Medicaid enrollees nationally—impacts vulnerable cancer patients reliant on timely access to complex specialty services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $212.3k | 4/17/26 |